advertisement
Abstract #12043 Published in IGR 7-1
Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy
Yuen NS; Cheung P; Hui SPJapanese Journal of Ophthalmology 2005; 49: 89-92
PURPOSE: To compare the effects of brimonidine 0.2% and apraclonidine 1% on intraocular pressure (IOP) and pupil size in patients undergoing laser peripheral iridotomy (LPI). METHODS: Forty patients (40 eyes) with occludable angle or angle-closure glaucoma requiring LPI were recruited. Patients were randomized to receive either brimonidine 0.2% or apraclonidine 1% before and after LPI. The IOPs were measured at 1, 2 and 3 h after LPI, and pupil size was measured before and at 45 min after eyedrop instillation. Both parameters were analyzed using the t test. RESULTS: There were 20 patients in each group. The baseline IOP was 17.1 ± 3.2 mmHg for the brimonidine group and 16.7 ± 2.8 mmHg for the apraclonidine group (P = 0.67) (t test). The mean IOP 3 h after laser treatment was 18.2 ± 7.8 mmHg for the brimonidine group and 15.7 ± 5.6 mmHg for the apraclonidine group (P = 0.25) (t test). There was no statistically significant difference between the two groups in the mean IOP changes at 1, 2, or 3 h after LPI. The mean change in pupil size after brimonidine was -0.33 ± 0.37 mm and after apraclonidine was +0.90 ± 0.87 mm. The difference was significant (P < 0.001). CONCLUSION: Brimonidine 0.2% was found to have an efficacy comparable to that of apraclonidine 1.0% in preventing post LPI IOP spikes. Apraclonidine 1.0% tends to have a pupil dilating effect while brimonidine 0.2% tends to constrict the pupil.
Dr. N.S. Yuen, Lo Ka Chow Ophthalmic Centre, Tung Wah Eastern Hospital, Hong Kong, People's Republic of China, nyuensy@netvigator.com.
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
12.2 Laser iridotomy (Part of: 12 Surgical treatment)
